Akut koroner sendromlu hastalarda 12 ledli elektrokardiyografi yeni parametreleri kullanılarak klaritromisinin aritmik etkilerinin değerlendirilmesi

Öz

Amaç: Klaritromisin yaygın olarak kullanılan kardiyak aritmik etkileri olan, QT uzaması ile torsade de point’ e sebep olan mikrolit antibiyotiktir. Eskiden akut koroner sendrom tedavisinde de kullanılmıştır. Bu çalışmanın amacı akut koroner sendromlu hastalarda kısa dönem klaritromisin kullanımının aritmik riski gösteren yeni EKG parametreleri üzerine olan etkisinin gösterilmesidir.

Gereç ve Yöntemler: 2002 yılında yürütülen akut koroner sendromu hastalarda 1000 mg/gün bir hafta klaritromisin tedavisinin endotel disfonksiyonu ve QT dispersiyonu üzerine olan etkilerinin gösterildiği çalışmanın EKG’leri geriye dönük olarak yeniden yeni EKG parametreleri için analiz edilmiştir. Atriyal ve ventriküler artmış aritmi riskini gösteren bu yeni EKG parametreleri; Tp–e interval, Tp-e/QTc oranı, maximum QTc, minimum QTc, QTc dispersionu, P-maximum, P-minimum ve P dalga dispersiyonu incelenmiştir.

Bulgular: 40 hasta çalışmaya dahil edilmiştir.  20 hasta klaritromisin tedavisi almış yirmisi almamıştır.  Klaritromisin tedavisi alan gurupta ortalama yaş 53,2 ± 8,0’dır. Kontrol gurubunda 58,9 ± 11,6’dır. Demografik karakterler ve tedavi öncesi EKG parametreleri her iki gurup için benzerdir ve karşılaştırılabilir. Fakat tedavi sonrası max QTc, min QTc, QTc dispersiyonu, Tp-e interval, TP-e/QTc, Pmax, Pmin ve P dalga dispersiyonu istatistiksel olarak anlamlı bir şekilde klaritromisin ile tedavi edilen gurupta kontrol gurubuna göre yüksektir (p<0.05, her bir parametre için).

Sonuç:  Klaritromisin tedavisi QT parametreleri yanı sıra yeni EKG parametreleri olan ve artmış ventriküler aritmi riskini gösteren Tp–e interval ve Tp-e/QTc oranını etkiler. Bununla birlikte atrial fibrilasyon artmış risk faktörü olan P-dalga parametreleri ve dispersiyonunu da etkiler. Tüm bu sonuçlardan akut koroner sendromlarda klaritromisin tedavisinin ventriküler ve atriyal aritmik riski arttırdığı çıkarılabilir.

Anahtar Kelimeler

• klaritromisin,aritmiler,kardiyak,akut koroner sendrom

Evaluation of arrhythmic effects of clarithromycin usage in patients with acute coronary syndrome via new parameters of 12 lead electrocardiography

Öz

Aim: Clarithromycin is a widely used macrolide antibiotic with arrhythmic effects causing torsade de pointes by elongating QT interval. Clarithromycin was used to treat acute coronary syndrome. we aimed to determine the acute effects of short-term clarithromycin treatment on novel ECG parameters in patients with acute coronary syndrome.

Material and Methods: The study we conducted in 2002 evaluated the effects of clarithromycin on endothelial functions and QTdispersion. We recently analyzed these patients’ ECGs performed before and one week after of 1000 mg/day clarithromycin treatment. We analyzed newly recognized parameters; Tp–e interval, Tp-e/QTc ratio, maximum QTc, minimum QTc, QTc dispersion values, P-maximum, P-minimum and P-wave dispersion to indicate the risk of atrial and ventricular arrhythmias.

Results: There were 40 patients included where 20 were treated with clarithromycin and 20 not. In the clarithromycin group, mean age of the patients was 53.2±8.0 and in control group 58.9±11.6. Demographic characteristics of patients were similar. All ECG parameters were comparable prior to clarithromycin treatment. However, following therapy, all parameters including max QTc, min QTc, QTc dispersion, Tp-e interval, TP-e/QTc, Pmax, Pmin, and P-wave dispersion were statistically significantly higher in clarithromycin treated group (p<0.05 for each).

Conclusion:Clarithromycin treatment not only affects QT parameters but also novel ECG parameters Tp–e interval and Tp-e/QTc ratio showing the risk of ventricular arrhythmias. It also affects P-wave parameters and dispersion that shows risk of atrial arrhythmias. We may conclude that clarithromycin treatment increases both ventricular and atrial arrhythmic risk during acute coronary syndromes.

Anahtar Kelimeler

• clarithromycin,arrhythmias,cardiac,acute coronary syndrome

Kaynakça

1. 1. Gysel M, Vieweg W, Hasnain M, Hancox J, Kunanithy V, Baranchuk A. Torsades de pointesfollowing clarithromycin treatment. Expert Rev Cardiovascular Ther 2013; 11: 1485-93.
2. 2. Kaab S, Crawford D, Sinner M et al. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes . Circ Cardiovasc Genet 2012; 5: 91-99.
3. 3. Hancox J, McPate M, El Harchi A, Zhang Y. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther 2008; 119: 118-32.
4. 4. Abbott G, Sesti F, Splawski I et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999; 97: 175-87.
5. 5. Göçer H, Şekuri, C, Bayturan Ö al. Akut Koroner Sendromlarda Kısa Süreli Klaritromisin Tedavisinin Akıma Bağlı Vazodilatasyon ve QT Dispersiyonu Üzerine Ektisi. Hipokrat Kardiyoloji Dergisi 2004; 31: 113- 17.
6. 6. Vieweg W, Hancox J, Hasnain M, Koneru J, Gysel M, Baranchuk A. Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports. Ther Adv Infect Dis 2013; 1: 121-38.
7. 7. Bril F, Gonzalez C, Di Girolamo G. Antimicrobial agents-associated with QT interval prolongation. Curr Drug Saf 2010; 5: 85-92.
8. 8. Kirbas A, Kirbas O, Daglar K et al. Novel indexes of arrhythmogenesis in preeclampsia:QT dispersion, Tp-e interval, and Tp-e/QT ratio. Pregnancy Hypertens 2016; 6: 38-41.

9. 9. Tukek T, Yildiz P, Akkaya V et al. Factors associated with the development of atrial fibrillation in COPD patients: the role of P-wave dispersion. Ann Noninvasive Electrocardiol 2002; 7: 222–27.
10. 10. Kose S, Aytemir K, Sade E et al. Detection of patients with hypertrophic cardiomyopathy at risk for paroxysmal atrial fibrillation during sinus rhythm by P-wave dispersion. Clin Cardiol 2003; 26: 431- 34.
11. 11. Malik M, Batchvarov VN. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol 2000; 36: 1749-66.
12. 12. Castro Hevia J, Antzelevitch C, Tornes Barzaga F et al. Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol 2006; 47: 1828-34.
13. 13. Braschi A, Abrignani MG, Francavilla VC, Abrignani V, Francavilla G. Age- and sex-based reference ranges for non-invasive ventricular repolarisation parameters. Int J Clin Pract 2017; 71: 12949.
14. 14. Lin L, Horigome H, Nishigami N, Ohno S, Horie M, Sumazaki R. Drug-induced QT-interval prolongation and recurrent torsade de pointes in a child with heterotaxy syndrome and KCNE1 D85N polymorphism. J Electrocardiol 2012; 45: 770-73.
15. 15.Li DQ, Kim R, McArthur E et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. CMAJ 2015; 187: 174-80.
16. 16.Wong AYS, Root A, Douglas IJ, Chui CS, Chan EW, Ghebremichael-Weldeselassie Yet al. Cardiovascular outcomes associated with use ofclarithromycin: population based study. BMJ 2016; 352.
17. 17. Chou HW, Wang JL, Chang CH, Lai CL, Lai MS, Chan KA. Risks of cardiac arrhythmia and mortality among patients using new‐generation macrolides, fluoroquinolones, and beta‐lactam/beta‐lactamase inhibitors: a Taiwanese nationwide study. Clin Infect Dis 2015; 60: 566-77.
18. 18. Trac MH, McArthur E, Jandoc R et al. Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. Can Med Assoc J 2016; 188: 120–29.
19. 19. Elming H, Holm E, Jun L et al. The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. Eur Heart J 1998; 19: 1391-400.
20. 20. Castro Hevia J, Antzelevitch C, Tornes Barzaga F et al. TpeakTend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol 2006; 47: 1828-34.
21. 21. Castro-Torres Y, Carmona-Puerta R, Katholi RE. Ventricular repolarization markers for predicting malignant arrhythmias in clinical practice. World J Clin Cases 2015; 3: 705-20.
22. 22. Dilaveris PE, Gialafos JE. P-wave dispersion: a novel predictor of paroxysmal atrial fibrillation. Ann Noninvasive Electrocardiol 2001; 6: 159-65.
23. 23.Cercek B, Shah PK, Noc M et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 2003; 361: 809-13.
24. 24. Kutlin A, Roblin MP, Hammerschla, Dunne M et al. Azithromycin for the secondary prevention of coronary heart disease events. The WIZARD study: A randomized controlled trial. JAMA 2003; 290: 1459-66.
25. 25. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study. Eur Heart J 1999; 20: 121-27.